Importantly, our data revealed both cancer cell-intrinsic as well as CAR T-cell-intrinsic pathways that could be exploited to overcome therapy resistance of TP53-mutant AML/MDS or to enhance therapeutic potency of CAR T-cells against TP53-mutant AML/MDS, respectively. This evidence concerns the gene TP53 and myelodysplastic syndrome.